Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Irbesartan + hydrochlorothiazide is a fixed-dose combination medication used to treat high blood pressure (hypertension) in adults whose blood pressure is not adequately controlled with either component alone. It combines two antihypertensive agents with complementary mechanisms: - **Irbesartan** is an angiotensin II receptor blocker (ARB), specifically antagonizing the AT1 subtype of the angiotensin II receptor. By blocking this receptor, it prevents vasoconstriction and aldosterone-mediated sodium retention caused by angiotensin II, leading to relaxation of blood vessels and reduced blood pressure. - **Hydrochlorothiazide** is a thiazide diuretic that acts on the distal convoluted tubule in the kidney to inhibit sodium reabsorption. This increases urinary excretion of sodium and water, reducing plasma volume and thereby lowering blood pressure. The combination provides an additive antihypertensive effect greater than either drug alone[1][4][8]. The product is available as oral tablets in various strengths.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on irbesartan + hydrochlorothiazide.